


PHARMACEUTICAL 2022



Coeptis Therapeutics Inc. Rank 456 of 475





PHARMACEUTICAL 2022



Coeptis Therapeutics Inc. Rank 456 of 475

The relative strengths and weaknesses of Coeptis Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Coeptis Therapeutics Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 350% points. The greatest weakness of Coeptis Therapeutics Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 795% points.

The company's Economic Capital Ratio, given in the ranking table, is -931%, being 654% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	2,180
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,765
Liabilities, Non-Current	1,650
Other Assets	4,572
Other Compr. Net Income	0
Other Expenses	190
Other Liabilities	0
Other Net Income	784
Property and Equipment	14
Research and Development	0
Revenues	75
Selling, General and Administrative Expense	14,118

Output Variable	Value in 1000 USD
Assets	6,766
Liabilities	4,415
Expenses	14,308
Stockholders Equity	2,351
Net Income	-13,449
Comprehensive Net Income	-13,449
Economic Capital Ratio	-931%